Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 13,075 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Back Pain
Interventions: Myelogram; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI (PT009) 320/9.6 μg, BFF MDI (PT009) 160/9.6 μg, FF MDI (PT005) 9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 121
States / cities: Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more

Conditions: Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Loma Linda, California • Los Angeles, California + 29 more

Conditions: Urinary Bladder Neoplasms
Interventions: Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy; Biological · Drug · Radiation
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 28
States / cities: Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more

Conditions: Herpes Zoster, HIV Infections
Interventions: ZOSTAVAX, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 43
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Graft-versus-Host Disease, Immune System Disorders
Interventions: Mycophenolate Mofetil, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Duarte, California • La Jolla, California • Stanford, California + 28 more

Conditions: HIV-1-infection
Interventions: VRC07-523LS, PGT121.414.LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 93
States / cities: Mobile, Alabama • Northport, Alabama • Little Rock, Arkansas + 82 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Physical Therapy, Support; Behavioral
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 4 Years to 18 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Memphis, Tennessee • Houston, Texas

Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: Adagrasib, Pembrolizumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 220
States / cities: Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: MEDI8897, Palivizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 1 Year
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 30
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 27 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: VX15/2503, Ipilimumab, Nivolumab; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis
Interventions: VX-809, Placebo, VX-770; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more

Conditions: Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
Interventions: KB109, No intervention; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Torrance, California • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: HIV Infections
Interventions: IMARA HIV Prevention Intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 17 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Fever
Interventions: Not listed
Lead sponsor: BioFire Diagnostics, LLC; Industry
Eligibility: Up to 3 Years
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Kansas City, Missouri + 3 more

Conditions: Atrial Fibrillation
Interventions: LARIAT + PVI, Pulmonary Vein Isolation; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 53
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 44 more

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Interventions: Pirfenidone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 27
States / cities: Phoenix, Arizona • Pomona, California • San Jose, California + 22 more

Conditions: Major Depressive Disorder
Interventions: Desvenlafaxine Succinate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 53
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 46 more

Conditions: Malignant Mesothelioma
Interventions: gemcitabine hydrochloride; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 84
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more

Conditions: Healthy
Interventions: IVX-A12, Placebo; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more

Conditions: Ischemic Heart Disease
Interventions: Not listed
Lead sponsor: Piedmont Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lymphoma
Interventions: carmustine, cytarabine, etoposide, thiotepa, stem cell transplant, G-CSF; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 126
States / cities: Anchorage, Alaska • Burbank, California • La Jolla, California + 81 more

Search by objective public record fields.

Measure of Cerebrospinal Fluid (CSF) Pressure Variation With Patient Positioning

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms

IMARA, Adapting SiHLE for Detained African American Adolescent Females

Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel

aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma